Dr. Hamlin on Next Steps With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

Paul A. Hamlin, MD
Published: Monday, Aug 21, 2017



Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

The initial experience as a phase I study has been encouraging, Hamlin explains, especially in the MCL cohort. These are patients with fairly aggressive disease and with blastic features whom experienced prominent responses to the therapy and were durable. It is likely that there will be more options in the future thats attack both processes, he adds.

Researchers already know that ibrutinib is effective as a single agent in MCL; therefore, attacking more than 1 pathway is what likely leads to the more durable responses, he concludes.


Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

The initial experience as a phase I study has been encouraging, Hamlin explains, especially in the MCL cohort. These are patients with fairly aggressive disease and with blastic features whom experienced prominent responses to the therapy and were durable. It is likely that there will be more options in the future thats attack both processes, he adds.

Researchers already know that ibrutinib is effective as a single agent in MCL; therefore, attacking more than 1 pathway is what likely leads to the more durable responses, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x